Janet A Hammond

US Patent:

20130345165, Dec 26, 2013

Filed:

Jun 11, 2013

Appl. No.:

13/915013

Inventors:

Tom W. Chu - Montclair NJ, US
Janet Hammond - Montclair NJ, US

Assignee:

Hoffman La-Roche Inc. - Nutley NJ

International Classification:

A61K 31/7068
A61K 31/427
A61K 31/7056
A61K 31/407
A61K 31/549

US Classification:

514 49

Abstract:

Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof, a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof, and a hepatitis C viral non-nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof, a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof, and a hepatitis C viral non-nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof.

US Patent:

20150272979, Oct 1, 2015

Filed:

Apr 6, 2015

Appl. No.:

14/679779

Inventors:

- Nutley NJ, US
Tom W. Chu - Montclair NJ, US
Janet Hammond - Montclair NJ, US

International Classification:

A61K 31/7068
A61K 31/549
A61K 31/407

Abstract:

Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof, a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof, and a hepatitis C viral non-nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof, a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof, and a hepatitis C viral non-nucleoside polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof.